Cookies help us to provide you a better service. In using our services, you agree with our use of cookies. Read More

October 18, 2016   |   News

BIAL launches opicapone, a novel treatment for Parkinson's disease patients with motor fluctuations in the UK

Porto, 17 October 2016 - Opicapone has now been launched in the UK for the treatment of adult Parkinson´s disease patients with motor fluctuations.

Opicapone was authorised by the European Commission in June 2016 as an adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Several therapeutic strategies are available to improve the signs and symptoms of Parkinson´s disease, mainly dopaminergic drugs avoiding the degradation or mimicking dopamine physiological effects. Levodopa remains the gold-standard treatment for the disease, although its long-term use causes what is known as motor complications, like end of dose motor complications or wearing-off. "Wearing-off" episodes may be improved with appropriate changes in the medication regimen, i.e. adding an extra dose of levodopa or using a COMT inhibitor.

“Studies have shown that opicapone is an effective, once-daily, an adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations. We are pleased that opicapone is now available in UK, a country where BIAL has recently opened an affiliate. Opicapone is the outcome of BIAL’s longstanding scientific commitment to neurological research. These launches also reflect BIAL’s increasing European footprint and the company’s mission to care for the Health of people worldwide”, comments António Portela, CEO of BIAL.

Share